Precise risk assessment based on clinical phenotypes and IFN scores to help implement early targeted and personalized therapy in high-risk patients may significantly improve the long-term prognosis of patients with anti-MDA5+ DM. The gene discussed is IFIH1; the disease is dermatomyositis.